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Abstract
Background: For immune monitoring studies during HIV vaccine clinical trials, whole blood
specimens from HIV seropositive (HIV+) patients may be collected at multiple sites and sent to a
central location for peripheral blood mononuclear cell (PBMC) isolation, cryopreservation and
functional evaluation. In this study we show a comparison of two PBMC preparation options, Ficoll
density gradient separation (Ficoll) and Cell Preparation Tubes (CPT) using shipped whole blood
specimens from 19 HIV+ patients (CD4 > 350, viral load < 50). The pre- and post- cryopreservation
performance of samples collected by these two methods were compared by assessment of antigen-
specific IFNγ expression in CD8+ and CD8- T cells, cellular viability, and cellular recovery.
Results: The results indicate that cryopreserved PBMC samples tested for CMV- and HIV- specific
interferon-gamma (IFNγ) expression performed equivalent to the respective fresh PBMC
processed under both collection conditions. Compared to fresh PBMC, the viability was
significantly lower for cryopreserved PBMC derived using Ficoll, although it was never less than
90%. There were no significant differences in the IFNγ response, viability, or recovery between
cryopreserved PBMC derived by Ficoll and by CPT.
Conclusion:  These data suggest that CPT is an efficient system for the collection and
cryopreservation of functionally active HIV+ PBMC, as well as a viable alternative to Ficoll gradient
separation.
Background
Therapeutic HIV vaccine clinical trials typically involve
the collection of whole blood specimens from HIV+
patients at multiple study sites, and the shipment of col-
lected samples to a central location for PBMC isolation
and evaluation [1,2]. Generally, clinical researchers prefer
to harvest and cryopreserve PBMC from blood samples
collected at pre-determined time points, and perform
assays at a later date or after a number of samples have
been accumulated. Cryopreservation and the evaluation
of samples at a central location have become standard
procedures for minimizing operator dependent variability
and to improve the precision and accuracy of immu-
noassays [2,3]. There are two typical whole blood collec-
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tion options available to clinical investigators, (1)
collection in evacuation type/VACUTAINER® tubes and
(2) collection in VACUTAINER® CPT™ (Cell Preparation
Tube). With collection method (1), samples are collected
and shipped to a central location for PBMC isolation
using Ficoll density gradient separation, while with collec-
tion method (2) whole blood samples are collected, and
processed by centrifugation at the collection site, and then
shipped to a central location for PBMC recovery.
Previous studies have shown that many factors can have
an effect on T cell functional responses including ship-
ment, storage, sample age, cryopreservation, and thawing
[1,3,4]. Some of these studies conclude that immunophe-
notyping, proliferation assays and functional assays
should only be done on fresh samples [1,3,4], while oth-
ers [2] have determined that use of frozen PBMC is a fea-
sible option for monitoring of immune function.
Therefore, for studies involving T cell responses as a meas-
ure of immune function, it is desirable to know that
PBMC samples are processed and handled in a manner
that will not degrade the ability of the cells to respond to
activation stimuli. It is likewise important that enough
viable cells are available after PBMC isolation and/or cry-
opreservation to perform the desired studies and that the
processing method not be technically complex. Com-
pared to CPT-processing, Ficoll density gradient separa-
tion is typically a more labor-intensive process requiring
an operator with more technical expertise and as such,
could result in operator variability with regard to cellular
recovery. Thus, to determine if CPT-processed samples
can be used as a standard replacement for Ficoll-processed
samples, we compared the two PBMC collection and
processing methods, using whole blood specimens from
19 HIV+ patients that were shipped to a central location,
to ascertain if one method had a significantly different
effect on viability, recovery and T lymphocyte responses in
antigen specific functional assays than the other method.
Since cryopreservation of patient samples has become a
standard practice in many clinical trials, the effect of cryo-
preservation of PBMC collected by both methods was also
evaluated in this study.
Results
To evaluate the effects of CPT and Ficoll processing on
HIV+ blood specimens, the study was designed as depicted
in the flow chart in Figure 1.
Cellular viability
Viability of the PBMC was assessed immediately after
PBMC preparation (fresh) and again immediately after
thawing (cryopreserved). The median viability of Ficoll-
processed fresh PBMC was significantly higher than that
of Ficoll-processed cryopreserved PBMC (p = 0.0005, Fig-
ure 2). There were no significant differences between CPT-
processed fresh or cryopreserved PBMC. Viability of
Ficoll-processed fresh PBMC was significantly higher
compared to CPT-processed fresh PBMC (p = 0.001, Fig-
ure 2). The viability of cryopreserved PBMC was always
greater than 90% for both processing methods and the
differences in viability of the cryopreserved PBMC pre-
pared by either method were not significant.
Cellular recovery
There were no significant differences between the recover-
ies (yield of viable cells) of fresh or cryopreserved PBMC
processed using Ficoll or CPT. The mean number of viable
cells recovered from CPT-processed fresh PBMC was 2.68
× 106 viable cells/ml of blood and the mean yield of
Ficoll-processed fresh PBMC was 2.98 × 106 viable cells/
ml of blood (Figure 3A). The median recovery of viable
PBMC after cryopreservation (percent of cells originally
cryopreserved) was equivalent for CPT-processed (48.0%)
and Ficoll-processed (47.9%) samples (Figure 3B).
Functional responses to antigen
The functionality of CD8 positive (CD8+) T cells, as meas-
ured by IFNγ expression, in fresh or cryopreserved PBMC,
processed by both methods was not significantly different
when stimulated with CMV-pp65 peptide mix (Figure 4A)
or HIV-p55 peptide mix (Figure 4B). The functionality of
Study design Figure 1
Study design. Viability, recovery, and intracellular cytokine 
staining of activated PBMC were compared for fresh and cry-
opreserved HIV+ PBMC processed by different methods 
according to the flow chart depicted here.
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CD8 negative (CD8- i.e. CD4+) T cells was significantly
different (p = 0.004) between CPT-processed and Ficoll-
processed fresh PBMC for CMV-pp65 peptide mix activa-
tion with the overall CPT-processed response being higher
than that of the Ficoll-processed. After cryopreservation
there was no significant difference between the methods
(Figure 4C). There were no significant differences for HIV-
p55 peptide mix activation in the fresh or after cryopreser-
vation comparisons within the CD8- group (Figure 4D).
Discussion
The immunological monitoring of antigen-specific T cell
responses is becoming a commonly used assessment tool
for therapeutic HIV trials [5] and as such, standardization
of sample handling and control of assay variables have
become an important necessity. In an effort to minimize
operator and inter-assay variability, and improve preci-
sion and accuracy, clinical specimens from HIV+ patients
are typically collected at different sites and sent to a cen-
tral location for processing and testing [2,3]. This also
facilitates the accumulation and archiving of samples (via
cryopreservation) for testing at a future time. Archiving of
samples is a desirable study feature, especially when sin-
gle-cell assays, such as cytokine flow cytometry (intracel-
lular cytokine staining) are used. Staining multiple
samples, accumulated over time, from the same donor
can potentially minimize within-donor variability, and
can also provide a means for avoiding time or operator
related staining inconsistencies. Therefore it is desirable to
know that samples are handled in a manner that will not
compromise the ability of the cells to respond to activa-
tion stimuli, that the viability of the cells is not signifi-
cantly altered, and that enough cells are recovered to
perform the desired assays. This study represents an anal-
ysis of the effects of PBMC processing method and cryop-
reservation on viability, recovery and functional response
Generally equivalent PBMC yields are obtained regardless of  processing method and no significant differences are seen in  cryopreserved PBMC recovery Figure 3
Generally equivalent PBMC yields are obtained 
regardless of processing method and no significant 
differences are seen in cryopreserved PBMC recov-
ery. The number (cells/ml) of viable "fresh" PBMC recovered 
after processing are depicted in graph A. Graph B depicts the 
percentage of thawed, viable PBMC recovered from the 
number originally frozen down. In these two graphs, each 
filled circle represents an individual donor and each donor is 
represented by the same color for each of the conditions 
tested. The "+" represents the median of all the donors in 
the category. The Wilcoxon signed rank test was used to 
determine significance.
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Viability of CPT-processed PBMC is not adversely 
affected by cryopreservation. The viability (percent of 
live cells) of fresh and cryopreserved PBMC was compared 
based on processing method. Significant difference (p) was 
determined by the Wilcoxon signed rank test. Each filled cir-
cle represents an individual donor and each donor is repre-
sented by the same color for each of the conditions tested. 
The "+" represents the median of all the donors in the cate-
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of HIV seropositive whole blood samples. Specimens
from 19 HIV+ donors were shipped to a central location
for processing and analysis. Since cryopreservation and
thawing can have deleterious effects on the viability,
recovery and function of PBMC [6-8], a consensus cryop-
reservation method [9,10] was used for all samples. The
same individual performed all PMBC processing (with the
exception of the CPT centrifugation step performed at the
blood collection site), counting, cryopreservation, func-
tional assays, staining, and analysis to minimize operator
variability.
The viability of a sample at the time of cryopreservation
will help predict the viability when the sample is thawed.
The low viability of a cryopreserved sample can adversely
affect in vitro functional responses [11]. Disis, et al state
that viabilities of > 70% predict consistent responses by T
cells in functional studies[10]. It is therefore important
that functional assays be performed with samples that are
cryopreserved using methods optimized to preserve cellu-
lar viability [9-11]. In this study we report that Ficoll-proc-
essed fresh PBMC have significantly better viability than
CPT-processed fresh PBMC. However, after cryopreserva-
tion there was no significant difference between the two
methods, indicating that if frozen samples were to be
used, both methods would perform equivalently. It is
unclear as to why the Ficoll-processed fresh PBMC have a
better viability than the CPT-processed fresh PBMC, but
since RBC are present only in the shipped specimens that
are eventually processed by Ficoll, one could speculate
that the RBC presence could be involved in maintaining
viability. The fact that the viability is not adversely
impacted by cryopreservation and thawing (viability is
>90%) indicates that archived samples are acceptable to
use in functional studies and should perform equivalently
to fresh samples. It should also be noted from the viability
results in Figure 2 that, for five CPT processed donors, the
viability of the fresh sample was lower than the viability
of the thawed cryopreserved sample. One explanation for
this could be counting error (either prior to, and/or after
cryopreservation), as there is little chance that cellular via-
bility would improve after cryopreservation. Another pos-
sible reason could be related to the removal of dead cells
from post-thaw washes. Despite this discrepancy, there is
no significant difference between the viability of the total
fresh and total cryopreserved CPT processed samples.
An important consequence of cryopreservation and thaw-
ing, that requires consideration, is diminished cell num-
bers. The number of cells recovered can be affected by the
wash steps involved and by variations with regard to the
number of cells originally placed in the freezing vessel.
Since it was important to ensure that a sufficient number
of PBMC were obtained to complete the comparisons for
each processing method, twice as much whole blood was
collected for the CPT method as was collected for the
Ficoll method. This feature was designed into the study
because of reports from other investigators (verbal com-
munications) that CPT-processing routinely yields less
PBMC per ml of whole blood than Ficoll-processing
yields. As it turned out, the difference in the mean number
Processing method does not adversely impact functional  response Figure 4
Processing method does not adversely impact func-
tional response. IFNγ expression by CD8+ and CD8- T 
Cells, in response to 6 hour activation with either CMVpp65 
peptide mix (A and C) or HIVp55 peptide mix (B and D), was 
used as a read-out of functional ability of the PBMC. Data dis-
played have been corrected for the unstimulated expression 
of cytokine. For FACS analysis, a lymphocyte (forward vs. 
side scatter) gate, and a CD3+CD8+ gate (A and B) or a 
CD3+CD8- gate (C and D) were applied. Significant differ-
ence (p) was determined by the Wilcoxon signed rank test. 
Each filled circle represents an individual donor and each 
donor is represented by the same color for each of the con-
ditions tested. The "+" represents the median of all the 
donors in the category.
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of viable cells recovered by the Ficoll process (2.98 × 106
cells/ml of blood) and the CPT method (2.68 × 106 cells/
ml of blood) was not significant (p = 0.3547). In situa-
tions where samples are cryopreserved for evaluation at a
later date, the numbers of fresh recovered PBMC are
important because they determine the number of cells
available for freezing and ultimately the post thaw recov-
ery numbers as well. In this study the median post-thaw
recovery of viable cells was approximately 50% of the via-
ble cells originally cryopreserved for samples processed by
both methods, and we did not see a significant difference
between these recoveries. Thus, the PBMC processing
method used should not matter when samples are to be
used post-cryopreservation. However, considerable num-
bers of cells were lost (relative to the number originally
frozen down) from the majority of donors in this study
for both processing methods. The reason for the cell loss
was not investigated in this study, but has been reported
by other investigators [2,6], and because of this loss it is
essential that the investigator collects an excess of sample
in order to ensure recovery of sufficient numbers after cry-
opreservation no matter which processing method is used
to obtain the PBMC.
Cytokine Flow Cytometry (CFC) assays can be used to
rapidly determine the ability of whole blood or PBMC to
respond to antigenic stimuli [12-15]. If the handling or
processing of samples has adversely affected a sample,
changes in the cytokine response may be evident. The
four-color flow cytometry assay employed for this study
uses IFNγ expression as a readout for the functional per-
formance of PBMC after shipping, processing and cryop-
reservation. The comparison of the magnitude of the
response to the antigenic stimuli used in this study (CMV-
pp65 or HIV-p55 peptide mixes) demonstrate that for the
CD3+/CD8+ T cells there were no significant differences in
response for either processing method, both fresh and
after cryopreservation. For the CD3+/CD8- T cells, a signif-
icant difference was seen between the freshly processed
CPT and Ficoll samples in response to CMV-pp65 peptide
mix, although the median responses are almost identical
(0.21% for CPT and 0.18% for Ficoll). From Figure 4, it
appears that this difference may have been due to one
"outlier" sample however, subsequent statistical analysis,
that excluded the outlier, still gave a significant response
(p = 0.006).
For the CFC assays performed in this study, all the func-
tional response data shown are the result of subtracting
the background (unstimulated) response. Occasionally,
an elevated background response (or spontaneous
cytokine production) was observed. In a study of healthy
CMV+ donors it was found that spontaneous cytokine pro-
duction was the result of CMV-responsive cells being reac-
tivated in-vivo [16]. In this study it is not known if the
unstimulated response is a result of in-vivo stimulation,
sample manipulation or some other mechanism. For
CD3+/CD8+  T cells, the backgrounds were generally
higher in the samples that were cryopreserved prior to
stimulation, with the background of the cryopreserved
Ficoll-processed samples being significantly higher (p =
0.002) than the background of the cryopreserved CPT-
processed samples (data not shown). The differences in
backgrounds of CD8+ T cells between fresh and cryopre-
served samples, among all the donors, were not signifi-
cant for either processing method (data not shown).
Similar to CD3+/CD8+ T cells, the backgrounds for CD3+/
CD8- T cells were elevated in the cryopreserved samples
prepared by both methods, and an increase in the back-
ground of the fresh Ficoll-processed samples was also
observed (data not shown). There was a significant differ-
ence (p = 0.03) in unstimulated response of CD8- T cells
between the fresh and cryopreserved CPT-processed sam-
ples (data not shown).
The dot plots in Figure 5 demonstrate IFNγ staining in
unstimulated, CMV-pp65 peptide mix- and HIV-p55 pep-
tide mix-stimulated PBMC for one of the donors in this
study. It was noted that the staining patterns varied
depending on the processing condition and this appeared
to be true with all the donors although there was no pat-
tern that could be consistently matched to a particular
processing method or activation condition (data not
shown). Because of this, it would seem prudent that an
experienced technician monitor all analysis in order to
insure that the analysis gates are adjusted properly, with
the ultimate goal of minimizing a potential source of
assay variability[17].
Previous investigators[13] have demonstrated that PBMC
and whole blood perform similarly when assessing anti-
gen-specific responses in both CD4+ and CD8+ T cell sub-
sets, with CFC assays, when no sample shipment was
involved. However, as discussed above, PBMC are the
standard sample used for clinical studies and as such this
study was done to compare the PBMC processing meth-
ods. It is apparent from the data presented here that CPT-
processed PBMC performed equivalently to Ficoll-proc-
essed PBMC, especially with regard to the fact that no mat-
ter which process was used, samples did not lose
functional activity upon cryopreservation and thawing.
Conclusion
With fresh samples, Ficoll-processed PBMC demonstrated
significantly better viability as compared to CPT-proc-
essed PBMC. With cryopreserved samples, CPT-processed
PBMC demonstrated better viability as compared to
Ficoll-processed PBMC but the difference was not signifi-
cant. Fresh and post-cryopreservation recoveries were not
significantly different between the two processing meth-BMC Immunology 2006, 7:11 http://www.biomedcentral.com/1471-2172/7/11
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ods. We also conclude that whether fresh or cryopreserved
PBMC are used, CPT is an efficient system for the collec-
tion of functionally active HIV+ PBMC as there was only
one instance (fresh CPT vs. cryopreserved CPT for CD8- T
cells) in which the results vary significantly. The results of
this comparative study indicate that PBMC prepared by
either method perform equivalently and that the use of
CPT to prepare PBMC from whole blood could be a viable
alternative to using Ficoll density gradient separation
when samples are collected at multiple study sites and
sent to a central location for processing and evaluation.
Methods
Patient characteristics
A total of 19 HIV-seropositive donors with CD4 count
greater than 350 and viral loads less than 50 (historically)
were recruited by Rush University in Chicago and The
Gladstone Institute in San Francisco. All patients were on
Antigen-specific stimulation of T cells results in cytokine expression Figure 5
Antigen-specific stimulation of T cells results in cytokine expression. Intracellular staining with IFNγ FITC/CD69 PE/
CD8 PerCPCy5.5/CD3 APC by Ficoll or CPT-processed PBMC from one representative HIV+ donor. The numbers displayed 
on the dot-plots represent the percentage of CD3+ and CD8+ lymphocytes that are expressing IFNγ and CD69 in response to 
antigen-specific stimulation or unstimulated control.
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highly active antiretroviral therapy (HAART) at the time of
blood collection.
Sample collection, processing and handling
Two 8 ml VACUTAINER® CPT™ (Cell Preparation Tube)
(BD, Franklin Lakes, NJ) and one 8 ml green top VACU-
TAINER®  (BD, Franklin Lakes, NJ), both containing
sodium heparin as the anti-coagulant, were collected from
each subject at each site. The CPT were processed at the
collection site, according to the manufacturer's instruc-
tions, by centrifugation at 1800 × G for 20 minutes at
room temperature within two hours of blood collection.
After centrifugation the CPT were gently inverted several
times. The processed CPT and the whole blood vacutainer
were shipped overnight, at ambient temperature, to San
Jose, CA. Upon arrival in San Jose, the whole blood from
the vacutainer was processed using Ficoll Paque (Amer-
sham Biosciences, Piscataway, NJ) to collect the PBMC.
Briefly, whole blood in the vacutainer tube was trans-
ferred to a 50 ml conical tube (BD Falcon, Franklin Lakes,
NJ), diluted to a volume of 30 ml with HBSS (Gibco Inv-
itrogen Corporation, Grand Island, NY), and underlayed
with 10 ml of Ficoll Paque. The 50 ml tubes were centri-
fuged at 400 × G for 30 minutes after which, the PBMC
were collected at the interface layer. PBMC were collected
from the processed CPT by gently inverting the collection
tube several times and drawing off the PBMC containing
plasma with a pipette. PBMC from both sets of tubes were
washed twice with HBSS and counted for recovery and
viability using 0.4% Trypan Blue (Sigma, St. Louis, MO).
Cryopreservation of PBMC
Aliquots of PBMC collected by both methods were cryop-
reserved using a consensus cryopreservation protocol as
previously described [9,10]. Briefly, a stock of 2X freezing
media containing 20% DMSO in RPMI (Sigma) with
12.5% human serum albumin (HSA, Gemini Bioprod-
ucts, Woodland, CA) was prepared and stored at 4°C. At
time of use, the 2X freezing media was kept cool on ice. A
minimum of 107 PBMC was frozen in order to ensure suf-
ficient recovery for the performance of functional assays
after thawing. Depending on the number of PBMC recov-
ered after processing, the cells were resuspended at a con-
centration of 1–2 × 107/ml in cold RPMI+12.5% HSA
without DMSO. An equal volume of 2X freezing media
was added drop wise to the cell suspension with swirling.
One ml of cell suspension was distributed to 2 ml cryovi-
als (Sarstedt, Inc., Newton, NC) on ice. Cryovials were
then transferred to a freezing container (Nalgene, Roches-
ter, NY), stored at -80°C for 24 hours and then transferred
to liquid nitrogen for long-term storage.
Thawing of PBMC
Upon removal from liquid nitrogen, cryovials were trans-
ferred to a 37°C water bath for rapid thawing. One ml of
warm (37°C) RPMI+10% fetal bovine serum+antibiotics
(cRPMI-10, all components from Sigma) was added drop
wise to each thawed cryovial and the total contents of the
cryovial were transferred to a 50 ml centrifuge tube (BD
Falcon, Bedford, MA) containing 8 ml of warm cRPMI-10.
Cells were centrifuged for 7 minutes at 250 × g, resus-
pended in a small volume of warm cRPMI-10 and
counted using Trypan Blue. Cell volume was then
adjusted for the appropriate amount needed for stimula-
tion (typically 5 × 106/ml).
Stimulation of fresh PBMC for CFC assays
If enough cells were available (approximately 107), PBMC
were stimulated, immediately after processing as previ-
ously described [15,18]. 200 µl of cell suspension in
cRPMI-10 was added to each well of a 96-well polypropyl-
ene V-bottom plate (BD Falcon) containing activation rea-
gents in a volume of 20 µl. The PBMC were typically
distributed at 1 × 106 cells/well but this concentration
ranged between 2 × 105 and 2 × 106cells/well depending
on the donor. CMV-pp65 peptide mix (BD Biosciences,
San Jose, CA; 1.7 µg/ml/peptide), HIV-p55 peptide mix
(BD Biosciences; 1.7 µg/ml/peptide), and Staphylococcal
enterotoxin B (SEB, Sigma; 1 µg/ml) were used as stimuli.
All samples received brefeldin A (BFA, BD Biosciences) at
a final concentration of 10 µg/ml. An unstimulated con-
trol, containing only BFA was also included. The cells were
then incubated for 6 hours at 37°C. After 6-hour stimula-
tion at 37°C all samples were held overnight at 18°C
using a programmable water bath. Cells were treated with
2 mM EDTA for 15 minutes at room temperature, fixed
with 100 µl 1X FACS Lysing Solution (FLS, BD Bio-
sciences) and, after sealing the 96 well plate with parafilm,
frozen at -80°C until ready to be stained.
Stimulation of cryopreserved samples for CFC assays
Frozen PBMC from both processing methods (CPT and
Ficoll – processed) were thawed as described above. Cells
in each sample were counted to determine viability and
recovery, and stimulated as described above for fresh. For
all patients, efforts were made to plate the cryopreserved
PBMC at the same concentration (cells/well) as their fresh
counterpart. After plating, the PBMC were rested over-
night in a 37°C, 7% CO2 incubator and then stimulated
as described above for fresh samples. After stimulation,
samples were frozen in FLS at -80°C in the 96 well plate,
until ready to be stained.
Staining of CFC assays
Intracellular staining was performed as previously
described [17]. When activated frozen samples from sev-
eral subjects had been accumulated, the plates were
removed from the freezer and thawed at 37°C. Upon
thawing, 100 µl of cold wash buffer (PBS/0.5%BSA/
0.1%NaN3) was added to each well and plates were cen-BMC Immunology 2006, 7:11 http://www.biomedcentral.com/1471-2172/7/11
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trifuged at 500 × G for 5 minutes after which the cells were
permeabilized with 200 µl 1X FACS Permeabilizing Solu-
tion 2 (BD Biosciences) for 10 minutes and washed twice
with 200 µl of wash buffer. Following permeabilization,
the samples were stained with a 4-color monoclonal anti-
body (mAb) cocktail containing IFNγ FITC, CD69 PE,
CD8 PerCP-Cy5.5 and CD3 APC (BD Biosciences) for 1
hour at room temperature in the dark. Plates were washed
two times and the cells were resuspended in 200 µl of 1%
paraformaldehyde in PBS. Stained samples were acquired
within 24 hours on a BD FACSCalibur equipped with a
High Throughput Sample loader using Multiwell Plate
Manager and CellQuest Pro software (BD Biosciences).
Data analysis
Data on PBMC from CPT and Ficoll samples were com-
pared for viability of fresh and frozen PBMC, recovery of
fresh and frozen PBMC, CD8+ and CD8- IFNγ responses to
antigenic stimuli, of frozen PBMC. If enough PBMC were
available, then analysis for CD8+ and CD8- IFNγ responses
was also performed for fresh PBMC. To evaluate func-
tional responses based on intracellular staining, activated
samples were compared to unstimulated samples (com-
parably stained) in order to account for spontaneous
cytokine production; hence no isotype control staining
was performed. Flow cytometry data were analyzed using
CellQuest Pro with automated (snap-to) gating algorithm
[15]. Statistical analysis was performed with the Wilcoxon
Signed Rank Test (StatView software, SAS Institute Inc.,
Cary, NC), the non-parametric version of the paired t-test.
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